Silence Therapeutics
SLN
9.82
-0.01
-0.10%
Silence Therapeutics
US · SLN
#3615 by market cap
9.82
-0.01
-0.10%
Live - 5344 symbols - heartbeat 291s ago
· 2026-10-08 07:29
Pre-market
10.02
+2.04%
After-hours
9.82
0.00%
- Market cap
- 610.35M
- P/E (TTM)i
- -7.61
- P/Bi
- 15.86
- EPSi
- -1.89
- Div yieldi
- 0.00%
- 52W posi
- 42%
Reader sentiment
Are you bullish or bearish on SLN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 11.1 percentage points.
Institutional ownership
- Held by institutions
- 38.68% -11.14pp
- Institutions
- 89 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund17.01%
Individual/Insider14.84%
VC/PE Fund12.98%
Mutual Fund5.96%
Private Company1.66%
Public Company1.07%
Other46.47%
Top holders as of 2026-08-12
Richard Griffiths
7.97% · 4.80M sh
Robert Keith
6.81% · 4.10M sh
TCG Crossover Management, LLC
5.04% · 3.03M sh
Artal Group S.A.
4.82% · 2.90M sh
Redmile Group, LLC
3.60% · 2.16M sh
Nantahala Capital Management, LLC
2.24% · 1.35M sh
Citadel Advisors LLC
2.21% · 1.33M sh
Nextech Invest Ltd.
1.58% · 952.40K sh
Millennium Management LLC
1.51% · 909.28K sh
Tetragon Partners UK LLP
1.27% · 764.26K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 2 sells
| Name | Role | Stake |
|---|---|---|
| Richard Griffiths | -- | 7.97% |
| Craig Tooman | Chief Executive Officer | 0.02% |
| James Ede-Golightly | Independent Non-Executive Director | 0.01% |
| Michael Davidson | Independent Non-Executive Director | 0.01% |
| Steven Romano | Chief Medical Officer and Head of Research & Development | 0.01% |
| David Lemus | Independent Non-Executive Director | 0.00% |
| Rhonda Hellums | Chief Financial Officer | 0.00% |
| Timothy McInerney | Director | -- |
| Ian Ross | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-05 | Richard Griffiths | -- | Private Disposition | -1,544,374 | -- |
| 2026-01-01 | Timothy McInerney | Director | Other Derivative Acquisition | +90,000 | $2.05 |
| 2026-01-01 | David Lemus | Independent Non-Executive Director | Other Derivative Acquisition | +90,000 | $2.05 |
| 2026-01-01 | James Ede-Golightly | Independent Non-Executive Director | Other Derivative Acquisition | +90,000 | $2.05 |
| 2026-01-01 | Steven Romano | Chief Medical Officer and Head of Research & Development | Other Derivative Acquisition | +300,000 | $2.05 |
| 2026-01-01 | Rhonda Hellums | Chief Financial Officer | Other Derivative Acquisition | +375,000 | $2.05 |
| 2025-12-21 | James Ede-Golightly | Independent Non-Executive Director | Other Derivative Acquisition | +90,000 | $2.15 |
| 2025-12-17 | Ian Ross | -- | Other Derivative Acquisition | +900,000 | $2.08 |
| 2025-12-13 | James Ede-Golightly | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2025-10-26 | Richard Griffiths | -- | Open Market Derivative Acquisiti | +22,000 | $5.45–7.75 |
| 2025-10-26 | Richard Griffiths | -- | Other Derivative Acquisition | +2,000 | $7.75 |
| 2025-08-02 | Richard Griffiths | -- | Open Market Derivative Dispositi | -20,000 | $5.45 |
| 2025-07-31 | Richard Griffiths | -- | Private Acquisition | +18,376 | -- |
| 2025-07-29 | Richard Griffiths | -- | Private Acquisition | +23,482 | -- |
| 2025-07-10 | Richard Griffiths | -- | Private Acquisition | +71,293 | -- |
| 2025-07-08 | Richard Griffiths | -- | Private Acquisition | +62,457 | -- |
| 2025-06-26 | Richard Griffiths | -- | Private Acquisition | +110,474 | -- |
| 2025-06-23 | Richard Griffiths | -- | Private Acquisition | +82,606 | -- |
| 2025-06-17 | Richard Griffiths | -- | Open Market Acquisition | +70,448 | $5.29 |
| 2025-06-11 | Richard Griffiths | -- | Private Acquisition | +39,305 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:29:00 · For reference only, not investment advice and not tailored to your situation.